# Evaluating a Novel Individualised Treatment Strategy for Carbapenem-Resistant Gram-Negative Bacteria Infections

> **NCT04202861** · NA · UNKNOWN · sponsor: **Singapore General Hospital** · enrollment: 594 (estimated)

## Conditions studied

- Antibiotic Therapy

## Interventions

- **DIAGNOSTIC_TEST:** In vitro antibiotic combination testing (iACT)

## Key facts

- **NCT ID:** NCT04202861
- **Lead sponsor:** Singapore General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-08
- **Primary completion:** 2022-09-30
- **Final completion:** 2023-03-31
- **Target enrollment:** 594 (ESTIMATED)
- **Last updated:** 2021-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04202861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04202861, "Evaluating a Novel Individualised Treatment Strategy for Carbapenem-Resistant Gram-Negative Bacteria Infections". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04202861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*